BioSpace News Archive

Carnegie Mellon University is gaining important insights from escape room participants on leadership, cooperation and diversity; learning why corporate teams are less successful than teams of strangers

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 portion of a study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in patients with newly diagnosed, non-severe lymphopenic high grade glioma (HGG), following standard radiation therapy and temozolomide.

Fluidx Medical Technology, Inc. released details on clinical use of their GPX Embolic Device for blocking flow to small microvasculature and large tumor feeding vessels.

Strong organizational foundation laid in 2020; continued pipeline execution amid COVID-19 and raised gross capital of $595.1 million Key 2020 pipeline achievements include proof of concept for FT-4202 in sickle cell disease; successful interim analysis of registrational Phase 2 trial of olutasidenib in R/R AML with IDH1m; and commencement of Phase 1 trial for FT-7051 in mCRPC

Monopar Therapeutics Inc. announced the publication of a peer-reviewed study titled “Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.” Urokinase plasminogen activator is an established biomarker in current breast cancer clinical practice guidelines and its presence is used to select appropriate drug treatment.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its request for Fast Track Designation for its drug, Annamycin,

AffaMed Therapeutics (“AffaMed”), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B financing

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that CEO John Sperzel released a book about his personal experience with a bloodstream infection (BSI) and sepsis, titled “Courage: Powerful Lessons in Leadership, Strength, and the Will to Succeed.”

Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the closing of the Royalty, License and Termination agreement (the “Agreement”) under which Takeda Pharmaceutical secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935)

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug Administration has allowed evaluation of nasal administration with Foralumab, a fully human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis patient at the Brigham and Women’s Hospital, Harvard University, Boston, MA.